Search Results
Search results for "GPCR drug discovery"
Results found for "GPCR drug discovery"
- Crinetics Presents Clinical And Research Results At ENDO 2022
Read more at the source #DrGPCR #GPCR #IndustryNews
- ShouTi Pharma CEO Dr. Raymond Stevens was interviewed by Moira Gunn of the NPR TechNation podcast
April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
(Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization Read more at the source #DrGPCR #GPCR #IndustryNews
- John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Read more at the source #DrGPCR #GPCR #IndustryNews
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
control neuropsychiatric symptoms in conditions such as schizophrenia. " Read more at the source #DrGPCR #GPCR
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
Provided by 5AM and Frazier â Pipeline is Built from Crineticsâ Core Nonpeptide Platform and Includes Drug (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Search for safer pain relief advances with new engineered compounds
in Florida have created a collection of new pain-relieving compounds that, like morphine and other drugs Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
(Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical potential global development of ADX71149 for the treatment of epilepsy. " Read more at the source #DrGPCR #GPCR
- Sosei Heptares reported its FY2021 financial result and provided an update on operational activities
February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
GPCRs represent major drug targets, as indicated by the fact that about 40% of all drugs currently used in clinical practice mediate their therapeutic effects by acting on GPCRs. Like many other organs, various GPCRs play a role in regulating liver function. It is predicted that more than 50 GPCRs are expressed in the liver. cells that regulate liver fibrosis, may lead to the development of drugs that can improve hepatic fibrosis
- ShouTi Pharma has a brand new website
Read more at the source #DrGPCR #GPCR #IndustryNews
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
chemistry decisions Why Live-cell High-Content Screening Matters for CB2 Ligand Profiling CB2 is a GPCR For GPCR programsâwhere trafficking, receptor reserve, and internalization are common confoundersâaccess What This Means for CB2 Drug Discovery Programs Taken together, the dataset offers several insights into how live-cell HCS can support CB2 ligand discovery: 1. For researchers working in cannabinoid pharmacology, inflammation, or GPCR-mediated analgesia, these
- Learn more about Neurocrine Biosciences with their new video
Read more at the source #DrGPCR #GPCR #IndustryNews
- Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E,
"Protecting neurons from death during oxidative and neuroexcitotoxic stress is key for preventing cognitive dysfunction. We uncovered a novel neuroprotective mechanism involving interaction between neurotrophic factor-α1 (NF-α1/carboxypeptidase E, CPE) and human 5-HTR1E, a G protein-coupled serotonin receptor with no previously known neurological function. Co-immunoprecipitation and pull-down assays confirmed interaction between NFα1/CPE and 5-HTR1E and 125I NF-α1/CPE-binding studies demonstrated saturable, high-affinity binding to 5-HTR1E in stably transfected HEK293 cells (Kd = 13.82 nM). Treatment of 5-HTR1E stable cells with NF-α1/CPE increased pERK 1/2 and pCREB levels which prevented a decrease in pro-survival protein, BCL2, during H2O2-induced oxidative stress. Cell survival assay in ÎČ-arrestin Knockout HEK293 cells showed that the NF-α1/CPE-5-HTR1E-mediated protection against oxidative stress was ÎČ-arrestin-dependent. Molecular dynamics studies revealed that NF-α1/CPE interacts with 5-HTR1E via 3 salt bridges, stabilized by several hydrogen bonds, independent of the serotonin pocket. Furthermore, after phosphorylating the C-terminal tail and intracellular loop 3 (ICL3) of NF-α1/CPE-5-HTR1E, it recruited ÎČ-arrestin1 by forming numerous salt bridges and hydrogen bonds to ICL2 and ICL3, leading to activation of ÎČ-arrestin1. Immunofluorescence studies showed 5-HTR1E and NF-α1/CPE are highly expressed and co-localized on cell surface of human hippocampal neurons. Importantly, knock-down of 5-HTR1E in human primary neurons diminished the NF-α1/CPE-mediated protection of these neurons against oxidative stress and glutamate neurotoxicity-induced cell death. Thus, NF-α1/CPE uniquely interacts with serotonin receptor 5-HTR1E to activate the ÎČ-arrestin/ERK/CREB/BCL2 pathway to mediate stress-induced neuroprotection." Read full article
- Dr. Alexander S. Hauser receives the Bachem award for peptide science
November 2021 Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Thomas P. Sakmar receives an honorary doctorate from Karolinska Institute
Read more at the source #DrGPCR #GPCR #IndustryNews
- Perkinsâ Head of Molecular Endocrinology and Pharmacology, Professor Kevin Pfleger, was appointed...
Read more at the source #DrGPCR #GPCR #IndustryNews
- First in Human: Early-stage COVID therapies hold promise against omicron variant
Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
Read more at the source #DrGPCR #GPCR #IndustryNews
- California gold rush for Sosei Heptares
Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Kevin Pfleger and Dr. Elizabeth Johnstone were awarded one of the 2022 Diabetes Research...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Positive Recommendation for Use of TAVNEOSâą (avacopan) in ANCA Vasculitis Adopted by European ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Exscientia welcomes Richard J. Law, as their new Chief Business Officer
partnerships and collaborations across pharma and #biotechâ and is an advocate for the role of #AI in drug discovery." Read more at the source #DrGPCR #GPCR #IndustryNews
- Exscientia is 10 years old this July!
We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates Weâre excited about delivering the next ten years of Exscientia and advancing AI to design better drugs #artificialintelligence #drugdesign #drugdiscovery" Read more at the source #DrGPCR #GPCR #IndustryNews
